Background/aim: Diaphragm thickness and mobility assessed by ultrasound in individuals with Chronic Obstructive Pulmonary Disease (COPD) reflect the function of the diaphragm. The aim of this study is to compare the diaphragm thickness, mobility, and thickening fraction in individuals with COPD of different severity and healthy individuals and examine the relationship between these parameters and pulmonary function test parameters. Materials and methods: A cross-sectional observational study design was used. Thirty individuals (mild = 11; moderate = 13; severe = 6) with COPD and 29 healthy male individuals aged between 40-75 years were included in the study. The individuals included in the study were evaluated between October 2020/May 2021. Pulmonary functions were measured with a spirometer, while diaphragm thickness, mobility, and thickening fraction were measured by ultrasound. Results: The right and left diaphragm thickness, mobility, thickness variation, thickening fraction, and mobility were lower in individuals with COPD than in healthy individuals (p < 0.05). The left Functional Residual Capacity (FRC) diaphragm thickness, right Total Lung Capacity (TLC), and FRC diaphragm thickness were higher in mild COPD than moderate COPD and moderate COPD than severe COPD (p < 0.05). The right diaphragmatic thickening fraction and rate were higher in mild COPD than in moderate and severe COPD (p < 0.05). The left mobility was lower in severe COPD than in mild COPD (p < 0.05). Conclusion: Diaphragm ultrasound parameters decrease as disease severity increases in individuals with COPD. We think that adding diaphragm ultrasound parameters together with pulmonary function test to the evaluation of individuals with COPD will provide additional contributions to determining the course of the disease.
Aim. We aimed to investigate the relationship between serum pregnancy-associated plasma protein A (PAPP-A) levels and obstructive sleep apnea syndrome (OSAS). Materials and Method. 44 patients with OSAS and 44 healthy adults were included in this study. The participants having rheumatic or systemic inflammatory disease, advanced liver or kidney failure, diabetes, heart failure, hypertension, pregnancy, prerenal azotemia, known history of coronary artery disease, any pulmonary disease, rhinitis, or atopy, history of major trauma or surgery within the last six 6 months, and inhaled nasal or systemic corticosteroid use or other anti-inflammatory medications and those with <18 years of age were excluded. Serum PAPP-A levels were determined by the Elisa method with the immune sandwich measuring method. Statistical analysis of the study was performed with SPSS 17.0 statistical analysis package program, and was considered as significant. Results. Serum PAPP-A levels of patients with OSAS (2.350 ng/ml (0.641–4.796)) were significantly higher () when compared with healthy controls (0.971 ng/ml (0.109–2.679)). There was a statistically significant difference in serum PAPP-A levels between groups of OSAS patients according to the classification of OSAS severity. Between the groups of patients with OSAS, serum levels of PAPP-A in moderate group was significantly higher when compared with severe OSAS group (). There was positive correlations between PAPP-A levels and night minimum (), and average oxygen levels (). There was a negative correlation between PAPP-A levels and AHI (). Conclusion. Higher PAPP-A levels in OSAS patients that were found in this study show inflammatory component in OSAS.
1 January 2018 in Archives of Clinical and Medical Case Reports